Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,945
  • Shares Outstanding, K 37,949
  • Annual Sales, $ 140,140 K
  • Annual Income, $ 67,040 K
  • EBIT $ -52 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.50
  • Price/Sales 0.27
  • Price/Cash Flow 0.53
  • Price/Book 0.65

Options Overview Details

View History
  • Implied Volatility 458.82% ( -96.31%)
  • Historical Volatility 57.82%
  • IV Percentile 94%
  • IV Rank 49.03%
  • IV High 923.84% on 06/24/24
  • IV Low 11.47% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 108
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,457
  • Open Int (30-Day) 2,042

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +43.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9006 +13.26%
on 12/20/24
1.4000 -27.14%
on 11/29/24
-0.1800 (-15.00%)
since 11/22/24
3-Month
0.9006 +13.26%
on 12/20/24
1.6200 -37.04%
on 10/18/24
-0.4600 (-31.08%)
since 09/23/24
52-Week
0.9006 +13.26%
on 12/20/24
3.0700 -66.78%
on 05/20/24
-0.8400 (-45.16%)
since 12/22/23

Most Recent Stories

More News
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYX : 1.0200 (+2.01%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 1.0200 (+2.01%)
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYX : 1.0200 (+2.01%)
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYX : 1.0200 (+2.01%)
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYX : 1.0200 (+2.01%)
Scynexis: Q2 Earnings Snapshot

Scynexis: Q2 Earnings Snapshot

SCYX : 1.0200 (+2.01%)
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 1.0200 (+2.01%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 1.0200 (+2.01%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...

SCYX : 1.0200 (+2.01%)
The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces an investigation of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX) on behalf of...

SCYX : 1.0200 (+2.01%)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 1.0767
2nd Resistance Point 1.0533
1st Resistance Point 1.0367
Last Price 1.0200
1st Support Level 0.9967
2nd Support Level 0.9733
3rd Support Level 0.9567

See More

52-Week High 3.0700
Fibonacci 61.8% 2.2413
Fibonacci 50% 1.9853
Fibonacci 38.2% 1.7293
Last Price 1.0200
52-Week Low 0.9006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar